Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-528-4
CAS number: 122-20-3
- No signs
of toxicity were noted during the in-life phase of the study. The doses
delivered were within 7-12% of the targeted dose levels. Between 94% and
96% of the administered radioactivity was recovered in the urine, feces,
14CO2, tissues / carcass, and final cage wash.
principle route of excretion was urine, which contained 81-85% of the
total dose. Feces contained 4-7%, 3-5% was eliminated as 14CO2, <2% was
recovered in the tissues/carcass and final cage wash. The amount of 14C
in the traps for volatile organics was negligible.
concentration of radioactivity was found in the initial blood sample
0.25 hours post-dose. The concentration decreased in a triexponential
manner. A 5-fold decrease in radioactivity was accomplished in the first
Half-lives for the rapid initial, middle, and terminal phases were 0.76,
3.6, and 38.5 hours, respectively. Most of the dose of radioactivity
(64-70%) was excreted in the urine 0-6 hours post-dosing. An additional
9-14% was excreted in the 6-12 hour interval. By 24 hours post-dosing,
82.8% of the dose was excreted. As with urine, 84.6% of the fecal
radioactivity was eliminated during the first 24 hours.
This study examined the metabolism and
excretion of triisopropanolamine-1-14C (14C-TIPA) in male rats when
administered concomitantly with 2,4 -dichlorophenoxyacetic acid (2,4
-D), and was conducted to support re-registration of products containing
the TIPA salt of 2,4 -D (2,4 -D TIPA).
Four male Fischer 344 rats were given a
single oral dose of a solution providing targeted doses of 10 mg 2,4
-D/kg and 10.7 mg 14C-TIPA/kg of body weight.
The concentration of radioactivity in the
plasma peaked 0.25 hr post-dosing at 4.48 +/- 1.19 ug eq/g plasma and
then decreased in a tri-exponential manner. Between 94 and 96% of the
administered radioactivity was recovered in the urine, feces, expired
14CO2, tissues/carcass and final cage wash. The major route of excretion
was the urine with approximately 80% of the dose excreted by this route
in the first 24 hr post-dosing and 81 to 85% excreted by 72 hr
post-dosing. The feces accounted for only 4 to 7 % of the dose. Expired
14CO2 accounted for 3 to 5% and the final cage wash ~1% of the dose.
Less than 1% of the administered radioactivity remained in the tissues
and carcass when these rats were sacrificed 72 hr post-dosing.
Essentially all radioactivity excreted in the urine represented
unchanged 14C-TIPA based on GC/MS and GC/MS/radiogas analysis of the
urine excreted 0 -12 hr post-dosing. Additionally, the urinary excretion
of 2,4 -D during the 0 -12 hr post-dosing interval (70.5% of the dose)
was nearly identical to that excreted during this interval following
oral administration of a 1 mg 2,4 -D/kg dose (69.3 +/- 13.1%).
These data demonstrate that orally
administered 14C-TIPA was rapidly absorbed and rapidly excreted
primarily in the urine as unchanged TIPA. Due to its rapid elimination,
14C-TIPA should not accumulate in the rat upon daily administration.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again